Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer.
Conclusions: We observed an overall decrease in brachytherapy (BT) monotherapy use since 2004 for localized prostate cancer. Despite similar survival outcomes, the use of HDR monotherapy declined relative to LDR.
PMID: 31523232 [PubMed]
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
More News: Academia | Brachytherapy | Cancer | Cancer & Oncology | Databases & Libraries | Hormonal Therapy | Hormones | Prostate Cancer | Statistics